<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2312">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131061</url>
  </required_header>
  <id_info>
    <org_study_id>CXCR4-2021</org_study_id>
    <nct_id>NCT05131061</nct_id>
  </id_info>
  <brief_title>68Ga-Pentixafor PET/CT for the Subtyping Diagnosis of Primary Aldosteronism: A Prospective Diagnostic Accuracy Study</brief_title>
  <official_title>68Ga-Pentixafor PET/CT for the Subtyping Diagnosis of Primary Aldosteronism: A Prospective Diagnostic Accuracy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qifu Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Hospital Of Southwest Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the value of 68Ga-Pentixafor PET/CT in the diagnosis of primary aldosteronism&#xD;
      subtype&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study. We will enroll 100 patients with definite diagnosis of PA using&#xD;
      adrenal venous sampling(AVS) as the gold standard for subtype to evaluate the value of&#xD;
      68Ga-pentixaforPET/CT in the diagnosis of PA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2021</start_date>
  <completion_date type="Anticipated">October 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with PA patients completed 68Ga-PentixaforPET/CT to evaluate its accuracy in diagnosis of PA subtype.</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects with PA patients completed 68Ga-PentixaforPET/CT to evaluate its accuracy in diagnosis of PA subtype.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Aldosteronism</condition>
  <arm_group>
    <arm_group_label>aldosterone-producing adenoma(APA)</arm_group_label>
    <description>PA confirmatory tests was positive; lateralization index in AVS≥4 or lateralization index 3-4in combination with contralateral suppression index≤1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bilateral adrenal hyperplasia(BAH)</arm_group_label>
    <description>PA confirmatory tests was positive; lateralization index in AVS&lt;3</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Aldosterone/renin ratio(ARR) testing</intervention_name>
    <description>ARR、AVS and CT were required for each patient and at least one confirmatory test is required</description>
    <arm_group_label>aldosterone-producing adenoma(APA)</arm_group_label>
    <arm_group_label>bilateral adrenal hyperplasia(BAH)</arm_group_label>
    <other_name>captopril challenge test(CCT) 、seated saline infusion test(SSIT)、fludrocortisone suppression test（FST）; AVS and computed tomography(CT)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A sample of 60 from the positive group and 40 from the negative group achieve 84% power to&#xD;
        detect a difference of 0.1500 between the area under the ROC curve (AUC) under the null&#xD;
        hypothesis of 0.7000 and an AUC under the alternative hypothesis of 0.8500 using a&#xD;
        two-sided z-test at a significance level of 0.05000. The data are discrete (rating scale)&#xD;
        responses. The AUC is computed between false positive rates of 0.000 and 1.000. The ratio&#xD;
        of the standard deviation of the responses in the negative group to the standard deviation&#xD;
        of the responses in the positive group is 1.000.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. PA diagnosis&#xD;
&#xD;
          2. Voluntary to sign on the informed consent and willing to complete all follow-up;&#xD;
&#xD;
          3. Have legal capacity and willingness to surgery&#xD;
&#xD;
          4. AVS succeeded&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. AVS failure or indeterminate subtype&#xD;
&#xD;
          2. Pregnant or lactate&#xD;
&#xD;
          3. Malignant tumor&#xD;
&#xD;
          4. Refuse to AVS&#xD;
&#xD;
          5. Complicated with Cushing syndrome&#xD;
&#xD;
          6. Glucocorticoid remediable aldosteronism (GRA) or Liddle syndrome&#xD;
&#xD;
          7. Rejected or intolerant to surgery, such as NYHA class 3 or 4, Severe anemia&#xD;
             (Hb&lt;60g/L)、stroke or acute coronary syndrome occurred within 3 months、end stage&#xD;
             cirrhosis、eGFR&lt;30ml/min/m2、untreated aneurysms, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>The First Affilated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifu Li, M.D., PhD.</last_name>
      <phone>023-89011552</phone>
      <email>liqifu@yeah.net</email>
    </contact>
    <contact_backup>
      <last_name>Ying Song, M.D.</last_name>
      <phone>023-89011552</phone>
      <email>shuiyunying@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006 Dec 5;48(11):2293-300. Epub 2006 Nov 13.</citation>
    <PMID>17161262</PMID>
  </results_reference>
  <results_reference>
    <citation>Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017 Apr 11;69(14):1811-1820. doi: 10.1016/j.jacc.2017.01.052.</citation>
    <PMID>28385310</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu Z, Yang J, Hu J, Song Y, He W, Luo T, Cheng Q, Ma L, Luo R, Fuller PJ, Cai J, Li Q, Yang S; Chongqing Primary Aldosteronism Study (CONPASS) Group. Primary Aldosteronism in Patients in China With Recently Detected Hypertension. J Am Coll Cardiol. 2020 Apr 28;75(16):1913-1922. doi: 10.1016/j.jacc.2020.02.052.</citation>
    <PMID>32327102</PMID>
  </results_reference>
  <results_reference>
    <citation>Mulatero P, Sechi LA, Williams TA, Lenders JWM, Reincke M, Satoh F, Januszewicz A, Naruse M, Doumas M, Veglio F, Wu VC, Widimsky J. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020 Oct;38(10):1929-1936. doi: 10.1097/HJH.0000000000002520.</citation>
    <PMID>32890265</PMID>
  </results_reference>
  <results_reference>
    <citation>Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004 Dec;136(6):1227-35.</citation>
    <PMID>15657580</PMID>
  </results_reference>
  <results_reference>
    <citation>Rossi GP, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J Jr, Naruse M, Deinum J, Schultze Kool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Christian Rump L, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Dun Wu K, Wu VC, Kratka Z, Barbiero G, Battistel M, Chang CC, Vanderriele PE, Pessina AC. Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. Hypertension. 2019 Oct;74(4):800-808. doi: 10.1161/HYPERTENSIONAHA.119.13463. Epub 2019 Sep 3.</citation>
    <PMID>31476901</PMID>
  </results_reference>
  <results_reference>
    <citation>Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, Deinum J. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009 Sep 1;151(5):329-37. Review.</citation>
    <PMID>19721021</PMID>
  </results_reference>
  <results_reference>
    <citation>Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.</citation>
    <PMID>26934393</PMID>
  </results_reference>
  <results_reference>
    <citation>Amar L, Baguet JP, Bardet S, Chaffanjon P, Chamontin B, Douillard C, Durieux P, Girerd X, Gosse P, Hernigou A, Herpin D, Houillier P, Jeunemaitre X, Joffre F, Kraimps JL, Lefebvre H, Ménégaux F, Mounier-Véhier C, Nussberger J, Pagny JY, Pechère A, Plouin PF, Reznik Y, Steichen O, Tabarin A, Zennaro MC, Zinzindohoue F, Chabre O. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook. Ann Endocrinol (Paris). 2016 Jul;77(3):179-86. doi: 10.1016/j.ando.2016.05.001. Epub 2016 Jun 15.</citation>
    <PMID>27315757</PMID>
  </results_reference>
  <results_reference>
    <citation>Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, Mustafa M, Schirbel A, Deutschbein T, Williams TA, Rhayem Y, Quinkler M, Rayes N, Monticone S, Wild V, Gomez-Sanchez CE, Reis AC, Petersenn S, Wester HJ, Kropf S, Fassnacht M, Lang K, Herrmann K, Buck AK, Bluemel C, Hahner S. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension. 2018 Feb;71(2):317-325. doi: 10.1161/HYPERTENSIONAHA.117.09975. Epub 2017 Dec 26.</citation>
    <PMID>29279316</PMID>
  </results_reference>
  <results_reference>
    <citation>Ding J, Zhang Y, Wen J, Zhang H, Wang H, Luo Y, Pan Q, Zhu W, Wang X, Yao S, Kreissl MC, Hacker M, Tong A, Huo L, Li X. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2656-2665. doi: 10.1007/s00259-020-04722-0. Epub 2020 Mar 23.</citation>
    <PMID>32206838</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>Primary investigator</investigator_title>
  </responsible_party>
  <keyword>PET CT; Primary aldosteronism; Adrenal venous sampling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludrocortisone</mesh_term>
    <mesh_term>Captopril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

